Please assess the completion status of the following clinical trial:

Trial Title: Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parkinson's disease diagnosis~* Currently taking a levodopa containing medication for Parkinson's disease~* Mild to Severe dyskinesia~* Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia.~* Stable medication regimen for at least 4 weeks prior to study.~Exclusion Criteria:~* Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation.~* Not able to follow verbal commands~* Not able to stand unsupported for at least 60 seconds~* Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia.~* Have proprioceptive deficits.~* Have a history of hepatic impairment~* Currently have severe renal impairment~* Currently have any other medical or psychiatric diagnosis that would preclude their ability to safely participate in the study.~* Significant cognitive impairment~* Pregnancy~* Breast-Feeding~* Unable to swallow study drug (capsule)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Buspirone (Type: EXPERIMENTAL): Two week titration up to 10 mg tablet/3 times a day for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Two week titration up to 3 tablets/3 times a day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).